From Croatia to MAHA: How an unapproved drug became the next hot peptide
Stat News • 2/3/2026
Summary
BPC-157 is an unapproved drug that has not received FDA approval. Despite this, it has gained traction and attention from MAHA.
Advertisement
Lindy Score Breakdown (V4.2)
59d
Age
1
Sources
from cluster
1432
Hours Since Seen
Final Score0/100
CategoryAntiLindy
StatusArchived
Recency Multiplier0% (0.5^1432/48)
Hero EligibleNo
Score is 0 because recency decay (0.5^1432/48 = 0.000000) reduced it below 0.5
Score BreakdownRisk 50
Source Reputation: Low-trust source (4/20 pts)
Consensus: Single source - no independent confirmation yet
Age: 59 days - proven survivor
Stories gain Lindy status through source reputation, network consensus, and time survival.
Breaking Similar stories
STAT+: Pharmalittle: We’re reading about FDA view on peptide compounding, Iran war hurting trial recruitment, and more
Stat News • 2 days ago
STAT+: Insilico Medicine CEO on how best to use AI in drug development
Stat News • 2 days ago
Opinion: My patient would rather take a peptide than a statin. That reveals an uncomfortable truth in medicine
Stat News • Today
STAT+: The biotech scorecard for the second quarter: 23 stock-moving events to watch
Stat News • 2 days ago
STAT+: Can a psychedelic ‘coach’ make ketamine therapy even more effective?
Stat News • 2 days ago
Why an ovary syndrome may get a new name: Men seem to have PCOS, too
Stat News • 2 days ago
Eli Lilly’s obesity pill approved by FDA, setting up fierce competition with Novo Nordisk
Stat News • 2 days ago
STAT reporter goes up against radiologists to spot deepfake X-rays
Stat News • 1 day ago
Supreme Court conversion therapy decision could ripple through medicine
Stat News • Today
Supreme Court rules against conversion therapy ban
Stat News • 2 days ago
Anti-Lindy Similar stories
STAT+: FDA approves Denali Therapeutics drug for Hunter syndrome
Stat News • 1 week ago
STAT+: Pharmalittle: We’re reading about an FDA OK for a rare disease drug, a grilling of the PTO chief, and more
Stat News • 1 week ago
STAT+: Pharmalittle: We’re reading about Trump pushing drug pricing policy, Chinese biotech licensing, and more
Stat News • 4 days ago
STAT+: Pharmalittle: We’re reading about a Merck acquisition, the rise of former Loxo execs at Lilly, and more
Stat News • 1 week ago